To the Editor:
Levetiracetam is a novel antiepileptic drug used in the treatment of the partial crisis as an add-on to other antiepileptic drugs. Although the underlying mechanism of action of levetiracetam is unknown, the metabolism of GABA appears to be involved. In particular, it may counteract neuronal hypersynchronization of the firing patterns of neurons in the substantia nigra pars reticulata and internal globus pallidus. 1 Levetiracetam has also been used in the therapy for the paroxysmal kinesigenic choreoathetosis and tardive dyskinesia.
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The substantia nigra pars reticulata and internal globus pallidus have been hypothesized to be critical areas in the development of dyskinesia. Levetiracetam may, through its peculiar hypersynchronizationinhibiting mechanism, play a role in the control of levodopa-induced dyskinesias, as observed in animal models of PD induced by MPTP at a dose of 60 mg/kg 4,5 as well as in parkinsonian patients (Zesiewicz et al., Paper presented at the 56th annual meeting of the American Academy of Neurology, San Francisco, 2004).
Our study included 16 parkinsonian outpatients with levodopa-induced dyskinesia ( Table 1 ). The patients were fully informed of the aims of the study and all gave their written informed consent.
This study was performed using an open-label observational design. The treatment given to the patients, optimized on each patient with the minimum effective dose of levodopa + dopaminergic agonists, was not changed for the duration of the trial. Levetiracetam was given in gradually increasing doses, starting with 125 twice daily (in the morning and in the evening). This dose was increased by 125 mg twice daily every week until a dose of 500 mg twice daily was reached. It was then increased by 500 mg every 5 days up to 2000 mg/day, or until a satisfactory result was achieved. The patients were followed for 3 months by means of monthly checkups performed by the same doctor, at the same hour of the day, and with the patient in the ON phase, using the UPDRS motor scale and AIMS each time: baseline (T0), 1 month (T1), and 3 months (T3). Moreover, the patients and their relatives recorded the presence and severity of the dyskinesia on a flowchart hourly every day and every hour.
Eight patients dropped out of the trial. Seven dropped out after the first 2 weeks owing to excessive sleepiness and a sensation of dizziness and confusion. They had not, in the weeks during which they had taken levetiracetam, reported any improvement in dyskinetic symptoms. The eighth patient continued the trial until the end of the second month before dropping out owing to a lack of efficacy of the drug (the AIMS and the UPDRS motor scores were unchanged). This patient reported daytime sleepiness only during the first 10 days. Eight patients concluded the study at 3 months. Although the drug was well tolerated, dyskinesia did not improve and UPDRS scores were unchanged during the follow-up. The administration of levetiracetam did not significantly change the duration of the dyskinesia (5.13 G 0.58 hours at baseline vs 4.75 G 0.38 hours 3 months later).
In the treatment of epilepsy, somnolence is a side effect in 10% 1 of patients. A recent preliminary study showed that levetiracetam reduces troublesome levodopa-induced dyskinesias, with changes in the AIMS scores revealing this trend in patients. Daytime somnolence in that trial accounted for a 33% dropout rate (Zesiewicz et al, Paper presented at the 56th annual meeting of the American 
